Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.66 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKACG | P22612 | 1/20 | 0.55 |
| ▸ | PRKACB | P22694 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239775 | 0.89 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL9505216 | 0.87 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL10150528 | 0.87 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL10239776 | 0.83 | STING1 (0.76) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL15865914 | 0.82 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL9702440 | 0.79 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL22352198 | 0.79 | STING1 (0.84) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL14260882 | 0.77 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL1106661 | 0.77 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DRAPGEF3 | |
| SCHEMBL13300472 | 0.77 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DRAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2012088155-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | PDE4A 22/4885PDE4B 28/4885PDE4C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.